A recent study reveals that people who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Published data in a major health publication points out that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such treatments must be aware of the potential of rapid rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to original mass in about 18 months.
Analyzing Treatments
The research, which reviewed 37 of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
The team point out that people who lose weight through diet and exercise usually experience a less rapid creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Experts suggest the mechanism of the drugs accounts for the amplified weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication leads to hunger is unsuppressed, making overeating much more probable."
A Chronic Issue?
Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the treatment should be considered life-long.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
User Accounts
People who have discontinued the medication describe a sudden resurgence of appetite.
"It was like a trigger flipping and you become ravenous," described one woman.
This difficulty is worsened if patients have not developed permanent dietary or behavioural modifications during treatment.
Widespread Interest
Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone fix and long-term success hinges on ongoing lifestyle support.
